Vancouver, British Columbia, November 10, 2022 – Genix Pharmaceuticals Corporation (TSXV:
GENX; OTCQB: GENPF) (“GENIX” or the “Company”) announces that it has appointed Buckley
Dodds CPA (“Successor Auditor”) as the Company’s auditor, replacing Harbourside CPA, LLP
The Board of Directors accepted the resignation of the Former Auditor of the Company effective
August 25, 2022. There were no reportable events, disagreements, or unresolved issues (as those
terms defined by Part 4.11 of National Instrument 51-102 – Continuous Disclosure Obligations)
between the Company and the Former Auditor.
The Audit Committee and Board of Directors have appointed the Successor Auditor as the
Company’s auditor effective November 4, 2022, until the next annual meeting of shareholders.
In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with
the required letters from the Former Auditor and the Successor Auditor, have been reviewed by
the Company’s Audit Committee and will be filed on SEDAR accordingly.
Genix Pharmaceuticals Corporation is a novel nutraceutical and generic ophthalmic drugs
company. The Company is focused on the research, development, manufacture, licencing and
sales of innovative healthcare products. In particular, these products include evidence-based,
proprietary over-the-counter (“OTC”) nutraceuticals, and other single molecule generic drugs
that have been shown to deliver consistent and verifiable results in various therapeutic areas.
The Company will market and sell its nutraceutical products in North America and select
countries. Genix will also begin to market and sell its generic drugs in Canada upon receiving
Health Canada approvals. Genix continues to conduct scientific R&D of new and innovative
products to support the health needs of mainstream consumers.
On Behalf of the Board of Directors,
Mr. Mahmoud Aziz
Genix Pharmaceuticals Corporation
2 of 2
For more information regarding Genix Pharmaceuticals Corporation, please contact:
Kevin Bottomley, Director
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking
statements that involve risks and uncertainties. These statements may differ materially from actual future
events or results and are based on current expectations or beliefs. For this purpose, statements of historical
fact may be deemed to be forward-looking statements. In addition, forward-looking statements include
statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”,
“anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”,
“prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a variety of important factors,
including, among others, the Company’s ability and continuation of efforts to timely and completely make
available adequate current public information, additional or different regulatory and legal requirements
and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the
Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk
factors that could cause actual results to differ from those contained in the forward-looking statements.
The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates
or to release publicly any revisions to any forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue
reliance on forward-looking statements